Across TCGA pan-cancer cohorts, KRT16P2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KRT16P2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher KRT16P2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRT16P2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

KIRC, BRCA, and GBM are the cancer types where KRT16P2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.054	0.881	<.001	46	view →
BRCA	OS	Median	IV	0.106	0.791	<.001	12	view →
GBM	DFS	Median	All	1.000	0.192	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KRT16P2 tumor-vs-normal RNA expression · all KRT16P2 data types